Delivery Order SPE2DB24D2105-SPE2DB25FAQAR
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $12,151.38 to AmerisourceBergen Drug Corp for the supply of Dupixent (dupilumab) 300 mg/2 mL pen injectors on August 1, 2025, with an ultimate completion date of August 4, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through...
- On August 5, 2025, the Defense Logistics Agency awarded a delivery order valued at $48,364.69 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injections. This firm fixed-price delivery order, which is not set-aside designated, represents a competitive award under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The products will be delivered to AmerisourceBergen's...
- The Defense Logistics Agency awarded a $9,133.25 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Dupixent 300 mg/2 ml pen injections. This is a firm fixed price delivery order with an ultimate completion date of July 29, 2025, representing a short-duration pharmaceutical supply contract. The award carries no set-aside designation, indicating it was competitively awarded through open procurement processes. AmerisourceBergen's corporate office in Conshohocken,...
- The Defense Logistics Agency awarded a $12,949.95 delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Dupixent 300 mg/2 mL pen injectors (2 mL units). This is a firm fixed-price delivery order with an ultimate completion date of July 21, 2025, and represents a non-set-aside award. The products will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Dupixent 300 mg/2 ml pen injections, with a contract ceiling value of $20,513.52 and an ultimate completion date of July 31, 2025. This is a firm fixed price delivery order with no set-aside designation, competitively awarded under AmerisourceBergen's existing contract vehicle. The place of performance is AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Dupixent 300 mg/2 mL pen injections with a ceiling value of $12,307.65. This is a firm fixed price delivery order with no set-aside designation, issued competitively to support federal medical procurement needs. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 8, 2025. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors with a firm fixed price ceiling value of $12,041.74. This competitively awarded, non-set-aside contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999.99 million through December 2026. The pharmaceutical distributor, headquartered in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors with a ceiling value of $10,591.02. This is a firm fixed price delivery order with no set-aside designation, awarded competitively to the prime contractor. The order is to be completed by August 6, 2025, with performance taking place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a...
- The Defense Logistics Agency awarded a delivery order valued at $15,459.09 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen (2 ml formulation) on August 8, 2025, with an ultimate completion date of August 11, 2025. This is a firm fixed price delivery order with no set-aside designation, competitively awarded under open competition. The place of performance is listed as AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. Dupixent is a biologic medication...
- The Defense Logistics Agency awarded a $12,356.56 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injections on July 29, 2025, with completion scheduled for July 30, 2025. This firm fixed-price contract, which received no set-aside designation, leverages AmerisourceBergen's position as a major pharmaceutical distributor supporting federal medical procurement. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- SPE2DB24D2105Indefinite Delivery Contract
- SPE2DB24D2105-SPE2DB25FAQARDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $27,256.30 on August 7, 2025, for the supply of Dupixent 300 mg/2 mL pen injections. The contract represents a firm fixed-price delivery order with an ultimate completion date of August 8, 2025, and will be performed at the contractor's Conshohocken, Pennsylvania facility. This award was competitively awarded with no set-aside designation. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and running through December 2026. As a major pharmaceutical distributor and prime vendor for federal medical procurement, AmerisourceBergen supplies a comprehensive range of pharmaceutical products and medical supplies to support military and veteran healthcare systems. The Dupixent supply under this delivery order supports the Defense Health Agency and other federal healthcare customers requiring biologic medications for immunological and dermatological conditions.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $27.3k | 8/7/25 |